Tissue Repair & Recovery Research Preliminary

KPV

C-terminal tripeptide of alpha-MSH (Lys-Pro-Val). Studied for anti-inflammatory properties, gut mucosal protection, and wound healing.

anti-inflammatorygutIBDwound healingalpha-MSHcytokines
Half-life
Very short; minutes to hours
SKUs
2
Evidence
Preliminary

KPV is a tripeptide consisting of the amino acids lysine, proline, and valine. It is the C-terminal fragment of alpha-MSH (alpha-melanocyte-stimulating hormone), which has known anti-inflammatory and wound-healing properties. KPV has been studied primarily for gut inflammation, skin conditions, and wound healing in preclinical and limited clinical research.

Gut Inflammation Research
KPV has been studied in animal models of inflammatory bowel disease. Research has shown anti-inflammatory effects in colitis models, with reductions in inflammatory cytokines and preservation of intestinal barrier function. Some interest has developed in oral KPV delivery for gut-specific applications.
Skin and Wound Healing
Because alpha-MSH and its fragments are involved in skin biology, KPV has been studied for wound healing and inflammatory skin conditions. Animal research shows accelerated wound healing and anti-inflammatory effects in skin injury models.
Broad Anti-Inflammatory Research
KPV's anti-inflammatory properties appear to be mediated through melanocortin receptors, particularly MC1R. Research has examined whether it can reduce inflammation in various contexts including infection-associated inflammation.
  • Anti-inflammatory effects in animal models of inflammatory bowel disease.
  • Wound healing acceleration in animal skin models.
  • Acts through melanocortin receptor pathways to reduce inflammatory signaling.
  • Limited human clinical trial data.

KPV research is predominantly preclinical. There are no completed large-scale human trials. The jump from animal IBD models to human inflammatory bowel disease is significant and uncertain. The appropriate dose, route, and delivery format for human use are not established. It is not FDA-approved for any use.

KPV is the last three amino acids of alpha-MSH, a hormone that plays roles in skin pigmentation, appetite, and inflammation control. The anti-inflammatory part of alpha-MSH's activity is largely contained in its C-terminal end, which is why researchers developed KPV as a smaller, more targeted fragment. KPV appears to activate melanocortin receptors on immune cells, which triggers a cascade that reduces the production of pro-inflammatory signals. In the gut, this may help calm the overactive immune response that drives conditions like colitis. The small size of the tripeptide may also allow it to be delivered orally with less degradation than larger peptides, which is a practical advantage for gut-targeted research.

KPV has not been evaluated in large human clinical trials and its safety profile in people is not established. Animal studies have not shown concerning toxicity. It is not FDA-approved. As a short peptide, it is expected to be broken down rapidly, but the pharmacokinetics in humans have not been thoroughly characterized in published research.

Preliminary

Most evidence comes from preclinical studies and case reports. Human data is limited and more research is needed.

Published Research Ranges
0.02–2mg/kg in animal studies; oral formulations studied for gut applications
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Alpha-MSH and Its Tripeptide KPV Inhibit Inflammatory Signaling in Intestinal Cells
American Journal of Physiology — Gastrointestinal and Liver Physiology • 2004  • DOI: 10.1152/ajpgi.00272.2003
View Source
KPV Tripeptide Has Anti-Inflammatory Effects in Experimental Colitis Models
Inflammatory Bowel Diseases • 2006  • DOI: 10.1097/01.MIB.0000235099.56553.64
View Source
Oral Delivery of the Alpha-MSH-Derived Peptide KPV in IBD: Nanoparticle Strategy
Biomaterials • 2010  • DOI: 10.1016/j.biomaterials.2010.02.042
View Source
Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review
 • 2025  • DOI: 10.7150/ijms.118118
View Source
Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease
 • 2025  • DOI: 10.1016/j.drudis.2025.104535
View Source
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials
 • 2023  • DOI: 10.3390/cells12141889
View Source
Metabolic reprogramming and epigenetic modifications on the path to cancer
 • 2022  • DOI: 10.1007/s13238-021-00846-7
View Source
Advances in covalent drug discovery
 • 2022  • DOI: 10.1038/s41573-022-00542-z
View Source
Antifibrotic and Anti-Inflammatory Actions of α-Melanocytic Hormone: New Roles for an Old Player
 • 2021  • DOI: 10.3390/ph14010045
View Source
Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
 • 2021  • DOI: 10.1038/s41579-020-0420-1
View Source
Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis
 • 2021  • DOI: 10.1021/acs.chemrev.0c01122
View Source
Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation
 • 2021  • DOI: 10.3390/cells10051056
View Source
Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
 • 2020  • DOI: 10.3389/fimmu.2020.02177
View Source
Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo
 • 2020  • DOI: 10.2147/ijn.s245326
View Source
Prescribed drugs containing nitrogen heterocycles: an overview
 • 2020  • DOI: 10.1039/d0ra09198g
View Source
Human Antimicrobial Peptides as Therapeutics for Viral Infections
 • 2019  • DOI: 10.3390/v11080704
View Source
Glucagon-like peptide 1 (GLP-1)
 • 2019  • DOI: 10.1016/j.molmet.2019.09.010
View Source
Coronavirus envelope protein: current knowledge
 • 2019  • DOI: 10.1186/s12985-019-1182-0
View Source
Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health
 • 2019  • DOI: 10.1186/s40168-019-0704-8
View Source
A Comprehensive Review on Lipid Oxidation in Meat and Meat Products
 • 2019  • DOI: 10.3390/antiox8100429
View Source
Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo
 • 2018  • DOI: 10.3390/biom8010004
View Source
Endothelial Cell Metabolism
 • 2018  • DOI: 10.1152/physrev.00001.2017
View Source
Cannabinoid Ligands Targeting TRP Channels
 • 2018  • DOI: 10.3389/fnmol.2018.00487
View Source
The complete European guidelines on phenylketonuria: diagnosis and treatment
 • 2017  • DOI: 10.1186/s13023-017-0685-2
View Source
Future Protein Supply and Demand: Strategies and Factors Influencing a Sustainable Equilibrium
 • 2017  • DOI: 10.3390/foods6070053
View Source
Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans
 • 2017  • DOI: 10.1155/2017/6501046
View Source
From Krebs to clinic: glutamine metabolism to cancer therapy
 • 2016  • DOI: 10.1038/nrc.2016.71
View Source
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
 • 2015  • DOI: 10.1021/acs.chemrev.5b00299
View Source
Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis
 • 2015  • DOI: 10.1016/j.virusres.2014.11.021
View Source
Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide
 • 2014  • DOI: 10.1155/2014/874610
View Source
Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends
 • 2026  • DOI: 10.3389/fimmu.2026.1739037
View Source
Cancer cachexia: molecular basis and therapeutic advances
 • 2026  • DOI: 10.1038/s41392-025-02331-7
View Source
Hydrogel Microspheres for Biomedical Applications
 • 2026  • DOI: 10.1002/smsc.202500453
View Source
Living Hydrogels: Harnessing Microorganism-Material Synergy for Next-Generation Therapeutics
 • 2026  • DOI: 10.1002/advs.202521766
View Source
Mechanistic studies of hydrogels in oral cancer treatment: Synergistic effects of drug delivery and immune modulation
 • 2026  • DOI: 10.1177/09636897261417200
View Source
The SLC-ome of membrane transport: From molecular discovery to physiology and clinical applications
 • 2025  • DOI: 10.1152/physrev.00001.2024
View Source
Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases
 • 2025  • DOI: 10.1021/acsnano.5c00700
View Source
Recent Advances in Polysaccharide-Based Hydrogels for Tumor Immunotherapy
 • 2025  • DOI: 10.3390/gels11030152
View Source
Advanced adhesion and targeting strategies to prolong gut residence time and improve eLBP efficacy in colonic diseases
 • 2025  • DOI: 10.1016/j.addr.2025.115722
View Source
Peptide-based therapeutic and delivery strategies for inflammatory bowel disease: challenges and future directions
 • 2025  • DOI: 10.1039/d5ra03731j
View Source
The Construction Strategy of Curcumin Nanomedicine Delivery System and Its Application in the Treatment of Ulcerative Colitis
 • 2025  • DOI: 10.2147/ijn.s573966
View Source
Fluorescent probes in autoimmune disease research: current status and future prospects
 • 2025  • DOI: 10.1186/s12967-025-06430-5
View Source
Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease
 • 2025  • DOI: 10.3390/pharmaceutics18010055
View Source
Recent advances in albumin-based nanoparticle drug delivery systems for intestinal disease treatment
 • 2025  • DOI: 10.1016/j.ijpx.2025.100387
View Source
Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease
 • 2024  • DOI: 10.1016/j.jcmgh.2024.03.005
View Source
Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics
 • 2024  • DOI: 10.1080/10717544.2024.2415580
View Source
Bioactive peptides and proteins for tissue repair: microenvironment modulation, rational delivery, and clinical potential
 • 2024  • DOI: 10.1186/s40779-024-00576-x
View Source
Bioactive materials for in vivo sweat gland regeneration
 • 2024  • DOI: 10.1016/j.bioactmat.2023.07.025
View Source
Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands
 • 2024  • DOI: 10.3390/ph17020256
View Source
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID
 • 2024  • DOI: 10.1038/s41538-024-00261-2
View Source
Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination
 • 2023  • DOI: 10.7759/cureus.49204
View Source
Interactions between Nanoparticles and Intestine
 • 2022  • DOI: 10.3390/ijms23084339
View Source
Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease
 • 2022  • DOI: 10.3390/pharmaceutics14091969
View Source
Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome
 • 2021  • DOI: 10.1016/j.addr.2021.114021
View Source
Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies
 • 2021  • DOI: 10.1016/j.apsb.2020.11.003
View Source
Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment
 • 2021  • DOI: 10.3389/fbioe.2021.675194
View Source
Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease
 • 2021  • DOI: 10.2147/ijn.s310952
View Source
Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease
 • 2021  • DOI: 10.2147/jir.s304101
View Source
Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
 • 2021  • DOI: 10.3390/md19040196
View Source
Peptide-Based Strategies for Targeted Tumor Treatment and Imaging
 • 2021  • DOI: 10.3390/pharmaceutics13040481
View Source

60 sources · Platform research library · Not generated by AI

KPV5KPV10

Combination use is not endorsed - provided for research context only.

Want More Detailed Research?

Ask the AI anything about KPV - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About KPV
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.